INNT
TOTAL INVALIDATION PROCESSED BY THE IB
05/09/2025
Voltar para busca
Dado oficial do USPTO
VECTURA V
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
10/09/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42
Data de depósito
03/11/2016
Data de registro
13/02/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/08/2024
Última transação
10/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
GB
Examinador
MARTIN, CHRISTINE
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the letter "V" made up of 6 oblique lines and a small triangle appearing next to the stylized word "VECTURA".
Titulares e representantes
Titulares
Vectura Limited
Representantes
Molly B. Markley Young Basile Hanlon & MacFarlane P.C.
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and biological preparations for medical purposesnamely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposesnamely the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genito-urinary systeminfectionsskin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposesnamely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposespowders for asthma inhalers; pharmaceutical and biological preparations for medical purposespowders for transdermal injection for the alleviation or prevention of painfor the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genito-urinary systeminfectionsskin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposesnamely for oral ingestion for the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genitourinary systeminfectionsskin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposesnamely for topical administration for the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genito-urinary systeminfectionsskin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposemedicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposespulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticalsdrug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purposenamely medicaments for the treatment of erectile dysfunctionmedicaments for the treatment of chronic obstructive pulmonary diseasemedicaments for the treatment of premature ejaculationmedicaments for the treatment of cystic fibrosismedicaments for the treatment of female sexual dysfunctionmedicaments for the treatment of migrainesmedicaments for the treatment of asthma
Classe 10
Medical apparatus and instrumentsnamely drug delivery devicesnamely drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods
Classe 42
Scientific researchdevelopmentdesignanalysistesting and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testing
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
16/08/2025
INPC
INVALIDATION PROCESSED
16/08/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
30/04/2025
C71T
CANCELLED SECTION 71
30/08/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/12/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
13/02/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/10/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/07/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/05/2018
FIMP
FINAL DISPOSITION PROCESSED
23/05/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/05/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
13/02/2018
GPNX
NOTIFICATION PROCESSED BY IB
08/12/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/11/2017
PUBO
PUBLISHED FOR OPPOSITION
28/11/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/11/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/11/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/11/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/10/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/10/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/10/2017
RFNT
REFUSAL PROCESSED BY IB
13/05/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/04/2017
RFRR
REFUSAL PROCESSED BY MPU
24/04/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/04/2017
CNRT
NON-FINAL ACTION WRITTEN
19/04/2017
MAFR
APPLICATION FILING RECEIPT MAILED
18/04/2017
DOCK
ASSIGNED TO EXAMINER
14/04/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/04/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/04/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VECTURA V ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.